In this study, RBPS was positively correlated with the expressions of CD274, CD276, CD80, CD86, CTLA4, FAS, PD1, and PDL1 in gliomas, indicating that the expressions of immune checkpoint-related genes increased with a high RBPS risk, thus leading to a worse prognosis. This evidence concerns the gene CD86 and central nervous system cancer.